|
|
|
Volumn 8, Issue 1, 2003, Pages 19-25
|
|
The value of preserving HIV-specific immune responses.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
DNA VACCINE;
IMMUNOLOGIC FACTOR;
INTERLEUKIN 2;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ANIMAL;
CD4+ T LYMPHOCYTE;
CELLULAR IMMUNITY;
CYTOTOXIC T LYMPHOCYTE;
DRUG COMBINATION;
DRUG EFFECT;
GENETICS;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNOLOGY;
LYMPHOCYTE COUNT;
PATHOGENICITY;
REVIEW;
T LYMPHOCYTE;
T LYMPHOCYTE SUBPOPULATION;
VIREMIA;
ACQUIRED IMMUNODEFICIENCY SYNDROME;
ANIMALS;
ANTI-HIV AGENTS;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
CD4-POSITIVE T-LYMPHOCYTES;
DRUG THERAPY, COMBINATION;
HIV INFECTIONS;
HIV-1;
HUMANS;
IMMUNITY, CELLULAR;
IMMUNOLOGIC FACTORS;
INTERLEUKIN-2;
LYMPHOCYTE COUNT;
T-LYMPHOCYTE SUBSETS;
T-LYMPHOCYTES;
T-LYMPHOCYTES, CYTOTOXIC;
VACCINES, DNA;
VIREMIA;
|
|
EID: 17744396795
PISSN: 14620308
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (6)
|
|
References (89)
|
